EU/3/19/2185: Orphan designation for the treatment of marginal zone lymphoma



Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2022 on request of the Sponsor.

On 25 July 2019, orphan designation EU/3/19/2185 was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for parsaclisib for the treatment of marginal zone lymphoma.


Key facts

Active substance
Intended use
Treatment of marginal zone lymphoma
Orphan designation status
EU designation number
Date of designation

Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

December 2022The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating